Abatacept therapy for rheumatoid arthritis in the setting of hepatitis C infection

Tina Dewan Mahajan, Roderick Hooker, Lisa Maher, Geri Brown, Andreas Reimold

Research output: Contribution to journalArticle

20 Scopus citations


Chronic hepatitis C in the setting of rheumatoid arthritis may be an obstacle to optimal management because of potential hepatotoxicity and adverse effects from immune suppression in these patients with a chronic infection. There are no reports in the literature discussing the use of abatacept, a T-cell costimulatory blocker, in patients with chronic hepatitis C. This article is the first report to describe the use of abatacept in 2 patients with rheumatoid arthritis and concomitant hepatitis C with favorable outcome.

Original languageEnglish (US)
Pages (from-to)332-334
Number of pages3
JournalJournal of Clinical Rheumatology
Issue number7
StatePublished - Oct 1 2010



  • Abatacept
  • hepatitis C infection
  • rheumatoid arthritis

ASJC Scopus subject areas

  • Rheumatology

Cite this